Page 44 - GPD-1-1

Gene & Protein in Disease Genetically engineered T cells in cancer immunotherapy

https://doi.org/10.1158 / 1078-0432.CCR-19-3259 https://doi.org/10.1038/nbt.4086
73. Beatty GL, O’Hara MH, Lacey SF, et al., 2018, Activity of 83. Pang N, Shi J, Qin L, et al., 2021, IL-7 and CCL19-secreting
mesothelin-specific chimeric antigen receptor T cells CAR-T cell therapy for tumors with positive glypican-3 or
against pancreatic carcinoma metastases in a phase 1 trial. mesothelin. J Hematol Oncol, 14(1): 118.
Gastroenterology, 155(1): 29–32. https://doi.org/10.1186/s13045-021-01128-9
https://doi.org/10.1053/j.gastro.2018.03.029 84. Hou AJ, Chen LC, Chen YY, 2021, Navigating CAR-T cells
74. Liu Y, Guo Y, Wu Z, et al., 2020, Anti-EGFR chimeric through the solid-tumour microenvironment. Nat Rev Drug
antigen receptor-modified T cells in metastatic pancreatic Discov, 20(7): 531–550.
carcinoma: A phase I clinical trial. Cytotherapy, 22(10): https://doi.org/10.1038/s41573-021-00189-2
573–580.
85. Tian Y, Li Y, Shao Y, et al., 2020, Gene modification strategies
https://doi.org/10.1016/j.jcyt.2020.04.088 for next-generation CAR T cells against solid cancers.
75. Qi C, Gong J, Li J, et al., 2022, Claudin18.2-specific CAR T J Hematol Oncol, 13(1): 54.
cells in gastrointestinal cancers: phase 1 trial interim results. 86. Liu G, Rui W, Zhao X, et al., 2021, Enhancing CAR-T
Nat Med, 28(6): 1189–1198. cell efficacy in solid tumors by targeting the tumor
https://doi.org/10.1038/s41591-022-01800-8 microenvironment. Cell Mol Immunol, 18(5): 1085–1095.
76. Zhang C, Wang Z, Yang Z, et al., 2017, Phase I escalating- https://doi.org/10.1038/s41423-021-00655-2
dose trial of CAR-T therapy targeting CEA(+) metastatic 87. Shi R, Tang YQ, Miao H, 2020, Metabolism in tumor
colorectal cancers. Mol Ther, 25(5): 1248–1258. microenvironment: Implications for cancer immunotherapy.
https://doi.org/10.1016/j.ymthe.2017.03.010 MedComm (2020), 1(1): 47–68.
https://doi.org/10.1002/mco2.6
77. O’Rourke DM, Nasrallah MP, Desai A, et al., 2017, A single
dose of peripherally infused EGFRvIII-directed CAR T cells 88. Chmielewski M, Kopecky C, Hombach AA, et al., 2011, IL-12
mediates antigen loss and induces adaptive resistance in release by engineered T cells expressing chimeric antigen
patients with recurrent glioblastoma. Sci Transl Med, 9(399): receptors can effectively Muster an antigen-independent
eaaa0984. macrophage response on tumor cells that have shut down
tumor antigen expression. Cancer Res, 71(17): 5697–5706.
https://doi.org/10.1126/scitranslmed.aaa0984
https://doi.org/10.1158 / 0008-5472.CAN-11-0103
78. Capsomidis A, Benthall G, Van Acker HH, et al., 2018,
Chimeric antigen receptor-engineered human gamma 89. Hu B, Ren J, Luo Y, et al., 2017, Augmentation of Antitumor
delta T cells: Enhanced cytotoxicity with retention of cross Immunity by Human and Mouse CAR T Cells Secreting
presentation. Mol Ther, 26(2): 354–365. IL-18. Cell Rep, 20(13): 3025–3033.
https://doi.org/10.1016/j.ymthe.2017.12.001 https://doi.org/10.1016/j.celrep.2017.09.002
79. Wang Y, Wang J, Yang X, et al., 2021, Chemokine receptor 90. Ma X, Shou P, Smith C, et al., 2020, Interleukin-23
CCR2b enhanced anti-tumor function of chimeric antigen engineering improves CAR T cell function in solid tumors.
receptor T cells targeting mesothelin in a non-small-cell Nat Biotechnol, 38(4): 448–459.
lung carcinoma model. Front Immunol, 12: 628906. https://doi.org/10.1038/s41587-019-0398-2
https://doi.org/10.3389/fimmu.2021.628906 91. Mariathasan S, Turley SJ, Nickles D, et al., 2018, TGFbeta
80. Li G, Zhang Q, Han Z, et al., 2021, IL-7 and CCR2b attenuates tumour response to PD-L1 blockade by
Co-expression-mediated enhanced CAR-T survival and contributing to exclusion of T cells. Nature, 554(7693): 544–
infiltration in solid tumors. Front Oncol, 11: 734593. 548.
https://doi.org/10.3389/fonc.2021.734593 https://doi.org/10.1038/nature25501
81. Liu G, Rui W, Zheng H, et al., 2020, CXCR2-modified 92. Chen X, Wang L, Li P, et al., 2018, Dual TGF-beta and
CAR-T cells have enhanced trafficking ability that improves PD-1 blockade synergistically enhances MAGE-A3-specific
treatment of hepatocellular carcinoma. Eur J Immunol, CD8(+) T cell response in esophageal squamous cell
50(5): 712–724. carcinoma. Int J Cancer, 143(10): 2561–2574.
https://doi.org/10.1002/eji.201948457 https://doi.org/10.1002/ijc.31730
82. Adachi K, Kano Y, Nagai T, et al., 2018, IL-7 and CCL19 93. Tang N, Cheng C, Zhang X, et al., 2020, TGF-beta inhibition
expression in CAR-T cells improves immune cell infiltration via CRISPR promotes the long-term efficacy of CAR T cells
and CAR-T cell survival in the tumor. Nat Biotechnol, 36(4): against solid tumors. JCI Insight, 5(4): e133977.
346–351. https://doi.org/10.1172/jci.insight.133977

Volume 1 Issue 1 (2022) 13 https://doi.org/10.36922/gpd.v1i1.114